Cancer systems immunology is a highly interdisciplinary field that is advancing our ability to understand and predict the complex behavior that orchestrates the interplay between tumors and the immune system.
Pre-existing enhancers interpret T cell signaling strength in an analogue manner to direct quantitative changes in gene expression within the context of an overall digital response.
Experiment-driven quantitative model of IL-2 secretion demonstrates how T cells integrate their digital antigen responses into an analog-scaled output.
Analysis of neo-splicetope-specific T cell responses strongly questions the idea that in vitro proteasome-catalyzed peptide splicing reaction simulates the in vivo situation with the same high fidelity as the in vitro generation of non-spliced epitopes.
A comprehensive literature review delineates the current knowledge of how systemic context, such as age and obesity, can impact CD8+ T cell function, anti-tumor immunity, and immunotherapy responsiveness.
HIV-specific T cells remain detectable for years in HIV-infected individuals on antiretroviral therapy and importantly, mostly (68%) recognize HIV viruses that have the capacity to rebound following treatment interruption.
A library of the paired peptide/HLA multimers and artificial APCs allows for construction of a large database of class I-restricted peptides and cognate tumor-reactive TCR genes at an unprecedented scale.
